Medication info
Empagliflozin and Metformin Sustained-Release Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Empagliflozin and Metformin Sustained-Release Tablet 5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkook Pharmaceutical Co., Ltd.
Appearance
Gray, double convex, oval-shaped sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501717 · Approved 2025.07.09 · Insurance code 653406050

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions). Special Populations Renal Impairment Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly Patients For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongkook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood glucose control issues in adults with Type 2 diabetes
  • cardiovascular disease
View approved original text

This medication helps improve blood glucose control in adults with Type 2 diabetes by using a combination of Empagliflozin and Metformin. It particularly acts as a complement to dietary and exercise therapies. Additionally, it is considered for use in patients with Type 2 diabetes who have accompanying cardiovascular disease, taking into account its effect on the occurrence of cardiovascular events. Therefore, this medication effectively enhances the treatment and blood glucose management of Type 2 diabetes.

How to take

Adult dose

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. This drug may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 4. Adverse Reactions and 6. Interactions). Special Populations Renal Impairment Because dose adjustment may be required based on renal function, assessment of renal function is recommended before starting this drug and periodically during treatment. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. Elderly Patients For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and helps lower blood glucose levels. However, certain precautions must be strictly followed when taking this medication. First, one of the ingredients, Metformin, can rarely cause a serious condition called lactic acidosis, which can be life-threatening, requiring utmost caution. Also, when taken with insulin or other diabetes medications, symptoms of hypoglycemia may occur, so blood glucose levels should be monitored closely. This medication should not be administered to patients with significantly decreased kidney function or severe liver dysfunction, and should be avoided in cases of acute infections, dehydration, or serious heart problems. Particularly, patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume only after kidney function returns to normal. This medication may increase the risk of genital or urinary infections; therefore, if infection symptoms appear, prompt consultation with a physician is advised. During treatment, regular checks of serum creatinine levels are essential to monitor kidney function. Additionally, this medication may reduce Vitamin B12 levels; hence, periodic checks of Vitamin B12 levels are recommended for long-term use. Women who are pregnant or breastfeeding should avoid taking this medication, and women of childbearing potential should consult a physician before taking it. Elderly patients or those at risk of fluid loss should be cautious to avoid dehydration or hypotension, and adequate fluid intake is necessary during treatment. It is advisable to avoid excessive drinking or alcohol consumption while taking this medication. When taking the tablets, do not crush or chew them; swallow them whole, and it is normal for the tablet coating to appear in the stool. Lastly, if any adverse reactions are suspected or symptoms worsen while taking this medication, notify healthcare professionals immediately.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficient vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 176 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • vaginal molluscum contagiosum
  • vulvitis
  • balanitis
  • perineal necrosis
  • increased blood creatinine
  • decreased glomerular filtration rate
  • gastrointestinal symptoms
  • chronic gastritis
  • various neurological disorders
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • intestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • positional vertigo
  • amnesia
  • carotid artery stenosis
  • diabetic neuropathy
  • facial paralysis
  • memory impairment
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory impairment
  • drowsiness
  • central nervous system origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • peripheral swelling
  • fever
  • facial swelling
  • chills
  • unusual sensations
  • swelling
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • double vision
  • hypertension
  • insomnia
  • dizziness
  • unstable angina
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • nasopharyngitis
  • shingles
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • dermoid cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • eye congestion
  • pathologic myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open ocular injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • palpitations
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorder
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • dysmenorrhea
  • positional dizziness
  • vertigo
  • angina

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a closed container to protect it from air and moisture. It is best kept at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Gray, double convex, oval-shaped sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.